Muscle Building Protocol

Overview

Peptide-based approaches to muscle building operate through mechanisms distinct from traditional anabolic compounds. Rather than directly binding androgen receptors, these peptides work primarily through the growth hormone (GH) and insulin-like growth factor (IGF) axis, myostatin inhibition pathways, and enhanced recovery signaling.

The muscle building protocol leverages three categories of peptides: GH secretagogues that stimulate endogenous growth hormone release, IGF-1 variants that directly support muscle protein synthesis at the tissue level, and Follistatin which modulates myostatin — a protein that acts as a natural brake on muscle growth.

The fundamental premise is that optimizing the GH/IGF-1 axis while reducing myostatin signaling creates a more favorable anabolic environment. However, peptides are not a substitute for progressive resistance training, adequate protein intake, and sufficient recovery. They are studied as potential amplifiers of the adaptive response to training, not replacements for the stimulus itself.

Compounds Involved

Protocol Structure

This protocol is organized into phases that progressively introduce compounds, allowing assessment of individual response and tolerability before adding complexity.

Phase 1: GH Secretagogue Foundation (Weeks 1–4)

The initial phase establishes the GH secretagogue base, which forms the backbone of the protocol. The combination of a GHRP (Ipamorelin) with a GHRH analog (CJC-1295 without DAC) produces a synergistic GH pulse that exceeds what either compound achieves alone.

Ipamorelin + CJC-1295 (no DAC):

• Dose: Ipamorelin 200–300 mcg + CJC-1295 100–200 mcg per injection
• Frequency: 2–3 times daily
• Timing: Administer on an empty stomach (fasted for at least 1 hour before and 30 minutes after). Common timing: upon waking, post-workout, and before bed
• Injection site: Abdominal subcutaneous
• Note: The pre-bed dose aligns with the natural nocturnal GH pulse and is considered the most important of the three daily administrations

For detailed GH secretagogue guidance, see the GH Secretagogue Protocol.

Phase 2: IGF-1 Addition (Weeks 5–8)

After establishing the GH secretagogue base, IGF-1 LR3 is introduced to provide direct anabolic signaling at the muscle tissue level.

IGF-1 LR3:

• Dose: 20–50 mcg per day (start at the lower end)
• Frequency: Once daily, post-workout on training days; morning on rest days
• Injection site: Subcutaneous, bilaterally into the trained muscle groups (split the dose between two sites)
• Duration: Typically run for 4-week cycles due to receptor desensitization concerns
• Important: IGF-1 LR3 has a significantly extended half-life compared to native IGF-1, which is why lower doses and cycling are emphasized

Continue Ipamorelin + CJC-1295 at the same doses established in Phase 1.

Phase 3: Follistatin Integration (Weeks 5–8 or 9–12)

Follistatin may be introduced alongside or following the IGF-1 phase, depending on individual response assessment.

Follistatin 344:

• Dose: 100 mcg per day (some protocols use up to 200 mcg)
• Frequency: Once daily
• Injection site: Subcutaneous, abdominal
• Duration: Typically 10–30 days. Follistatin protocols tend to be shorter cycles due to the potency of myostatin inhibition and limited long-term human data
• Note: Follistatin has a relatively short half-life and research on optimal cycling is still limited

Phase Summary Table

Training Synergy

Peptides in this protocol are studied as amplifiers of the training stimulus. Key training considerations include:

• Progressive overload: The foundation of hypertrophy remains mechanical tension applied through progressively heavier or more voluminous training
• Post-workout timing: IGF-1 LR3 administration immediately post-training may capitalize on the exercise-induced increase in IGF-1 receptor sensitivity
• Training volume: Higher training volumes may produce a greater adaptive response when GH/IGF-1 signaling is optimized
• Recovery capacity: Enhanced GH pulsatility may support faster recovery between sessions, potentially allowing increased training frequency
• Sleep quality: GH secretagogues administered before bed may enhance the restorative quality of sleep, which is when the majority of tissue repair and growth occurs

Important Considerations

• Fasting requirements are critical: GH secretagogues must be administered in a fasted state. Insulin and elevated blood glucose suppress GH release, negating the purpose of these compounds. Wait at least 1 hour after eating before administration, and at least 30 minutes after injection before consuming food.
• Blood glucose monitoring: IGF-1 LR3 can lower blood glucose levels. Monitoring blood glucose, especially during initial use, is advisable. Symptoms of hypoglycemia (shakiness, sweating, confusion) should be taken seriously.
• Cycling is important: IGF-1 LR3 is typically cycled (4 weeks on, 4 weeks off) to prevent receptor desensitization. Follistatin cycles tend to be even shorter. GH secretagogues can generally be run for longer periods, though periodic breaks are common practice.
• Dose escalation: Starting at the lower end of dosing ranges and titrating upward based on response and tolerability is the standard approach.
• Lab monitoring: Monitoring IGF-1 blood levels, fasting glucose, and insulin levels provides objective data on protocol response. See GH/IGF-1 Research for relevant biomarkers.
• Not a shortcut: Even with optimized peptide protocols, muscle building requires consistent progressive training, adequate protein intake (typically 1.6–2.2 g/kg/day), and sufficient sleep.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.